Navigation Links
Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
Date:5/27/2009

A Drug's Activity Against Anaerobes is the Leading Attribute in Antibiotic Selection, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., May 27 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that surveyed physicians will increase prescribing of Wyeth's Tygacil, Merck's Invanz and Johnson & Johnson's Doribax in the next five years for the treatment of intra-abdominal infections because of their potent broad-spectrum activity and efficacy against gram-negative and anaerobic organisms.

"Treatment for intra-abdominal infections is largely empiric," stated Lisa Arias, analyst at Decision Resources. "A variety of organisms, particularly gram-negative aerobic bacteria and anaerobes, are documented in patients with an intra-abdominal infection. In fact, the leading attribute that physicians surveyed look for in a drug to treat intra-abdominal infections is its activity against anaerobes."

The new report entitled Hospital Anti-Infectives Insight Series: Intra-Abdominal Infections also finds that 96 percent of surveyed physicians cite a drug's activity against anaerobes as the leading attribute in antibiotic selection. Intra-abdominal infections are often polymicrobial in nature and involve anaerobes specific to the etiology of the infection, so activity against these organisms is advantageous even without bacterial confirmation.

"Physicians also rank availability in intravenous formulation and a low propensity to induce resistance as other important drug attributes that influence their selection in antibiotics," added Ms. Arias. "While some agents with anaerobic and gram negative activity, such as carbapenems, address some of these attributes, no antibiotic captures all of the top most important attributes which leaves opportunity for novel products to differentiate themselves."

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

Members of the media are welcome to attend our upcoming webinar entitled Hospital Anti-Infectives Insight Series: Analyzing Prescribing Trends and Emerging Therapies in the Hospital Antibiotic Market. The webinar will be held on Wednesday, June 17, 2009 at 10 a.m. EDT. For more information, please contact Gisselle Morales at 781.296.2691 or e-mail at gmorales@dresources.com.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
6. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
9. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
11. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase ... ... ... ... ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK will be exhibiting ... beyond the implant at the Heart Rhythm Society,s 37 ... San Francisco . "Physicians ... quality of patient care and satisfaction possible. Part of ... and every tomorrow," said Marlou Janssen , President, ...
(Date:5/3/2016)... 3, 2016 Intec Pharma Ltd. ... biopharmaceutical company, today announced the appointment of Pnina ... "Ms. Strauss-Levy has 15 years of experience ... an outstanding track record, having supported the advancement of ... processes in the United States ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... ... for knees, ankles, and elbows. Engineered with athletes in mind, OMNIFORCE offers ... (opposed to ineffective circular knitting, common in the industry) produces premium flat-knit ...
(Date:5/4/2016)... British Columbia – , ... ... Wimmzi , a manufacturer of innovative infant and child products, today ... toys. But their ability to help babies deal with teething pain ... FDA approved, contain no toxic gels, and are BPA-, PVC-, and ...
(Date:5/4/2016)... California (PRWEB) , ... May 04, 2016 , ... With ... Research (AACR) honors the month of May as National Cancer Research Month. According to ... million new diagnoses of cancer with predications of one in four Americans dying as ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Over 40 athletic ... in the state capitol for the annual “Hike to Harrisburg” advocacy day. The ... The Winter Group, PATS lobby Group. The goal for the day was to ...
(Date:5/4/2016)... ... May 04, 2016 , ... International Conference on ... July 25-27, 2016 at Las Vegas. It aims to bring together academicians, scientists, ... and research organizations across the globe; making the conference a perfect platform to ...
Breaking Medicine News(10 mins):